"Dacarbazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
| Descriptor ID |
D003606
|
| MeSH Number(s) |
D02.925.200 D03.383.129.308.240
|
| Concept/Terms |
Dacarbazine- Dacarbazine
- Dimethyl Imidazole Carboxamide
- Carboxamide, Dimethyl Imidazole
- Imidazole Carboxamide, Dimethyl
- DTIC
- ICDT
- Decarbazine
- 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
- DIC
- Dimethyl Triazeno Imidazole Carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Dacarbazine".
Below are MeSH descriptors whose meaning is more specific than "Dacarbazine".
This graph shows the total number of publications written about "Dacarbazine" by people in this website by year, and whether "Dacarbazine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 6 | 7 |
| 2009 | 2 | 2 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 4 | 3 | 7 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 3 | 3 |
| 2014 | 3 | 6 | 9 |
| 2015 | 4 | 1 | 5 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dacarbazine" by people in Profiles.
-
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 09 23; 385(13):1196-1206.
-
Clinicopathologic features and therapy outcome in childhood Hodgkin's lymphoma: a report from tertiary care center in Saudi Arabia. J Egypt Natl Canc Inst. 2021 Aug 16; 33(1):21.
-
Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2018 08; 40(6):e338-e342.
-
Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature. J Med Case Rep. 2018 May 30; 12(1):151.
-
High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
-
VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Jan; 65(1).
-
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. Neurosurgery. 2016 Mar; 78(3):E466-73.
-
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016 Jan; 126(1):185-192.
-
Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):306-314.
-
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87.